Biophan Appoints Stan Yakatan to Board of Directors.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, announced today that Stan Yakatan, well known biomedical industry executive and thought leader, has joined the Company's Board of Directors.

Mr. Yakatan has 30 years experience in life sciences and biotechnology related industries. In addition, he is CEO of Katan Associates, a consulting/advisory group, through which he has served as a senior advisor to various healthcare companies over the last ten years.

Prior to this, Mr. Yakatan was CEO of Quantum Biotechnologies Inc.; CryoSurge; Cystar, Inc.; and Proteine Performance. He is frequently invited to speak at technology and financial seminars, capitalizing on his wealth of knowledge in the industry and his experience in raising capital.

Michael Weiner, CEO of Biophan, said, "Stan will be an invaluable addition to Biophan's Board of Directors. We look forward to his guidance as we continue to pursue our strategic plan--developing partnerships and licensing agreements for our MRI related technologies, and working to launch the MYO-VAD[TM] cardiac support system."

Stan Yakatan commented, "I'm looking forward to working with the company. Biophan's IP portfolio and commitment to technology leadership position the business well. The outlook is very exciting."

Mr. Yakatan has founded or co-founded over 15 companies in the U.S. and abroad. He sits on the board of several private and public companies, as well as advising some of the world's leading venture capital firms, and is the biotech advisor to the Premier of Victoria, Australia. He is currently serving as Chairman of Grant Life Sciences, Inc. (OTCBB: GLIF), a company developing a revolutionary test for the screening of cervical cancer. Mr. Yakatan attended University of Pennsylvania's Wharton School of Business.

About Biophan

Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company licenses its technologies which improve the MRI safety and image compatibility of medical devices to leading device manufacturers. In addition, the Company is helping to commercialize the MYOTECH MYO-VAD[TM], a new, MRI-compatible cardiac recovery system which has significant potential to improve the treatment of many forms of heart disease. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.